Evidence map›Paper›PMID 37591212›Full record

SynthesisOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde2023

Anti-Vascular Endothelial Growth Factor Therapy Regimens for Polypoidal Choroidal Vasculopathy: A Systematic Review.

Andrew Mihalache, Amin Hatamnejad, Nikhil S Patil, Marko M Popovic, Rajeev H Muni, Peter J Kertes, David T Wong

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Andrew MihalacheTemerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, andrewmihalache02@gmail.com.
Amin HatamnejadMichael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Nikhil S PatilMichael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Marko M PopovicDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Rajeev H MuniDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Peter J KertesDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
David T WongDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
McMaster University · CAUniversity of Toronto · CAHealth Sciences Centre · CAUnity Health Toronto

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are no guidelines on the optimal anti-vascular endothelial growth factor (anti-VEGF) monotherapy regimen for patients with polypoidal choroidal vasculopathy (PCV). In this study, we aimed to assess the comparative safety and efficacy of different treatment regimens of anti-VEGF monotherapy for PCV.

methodsWe conducted a systematic literature search on Ovid MEDLINE, Embase, and Cochrane Library from January 2000 to May 2023 for comparative articles reporting on different treatment regimens of anti-VEGF agents in PCV. Our primary outcomes were the final best-corrected visual acuity (BCVA) and the change in BCVA from baseline. Secondary outcomes were the final retinal thickness (RT), the change in RT from baseline, the rate of polyp closure, and the incidence of adverse events.

resultsA total of 10,440 studies were screened, and seven studies reporting on 636 eyes with PCV at baseline were included in this systematic review. One RCT of 53 eyes found a similar final BCVA, change in BCVA from baseline, final RT, and complete polyp closure rate between a treat-and-extend (T&E) regimen and a bimonthly fixed-dosing regimen of aflibercept. This trial also found superiority of T&E for change in RT from baseline. One observational study of 33 eyes found a similar BCVA at last study observation between a pro re nata (PRN) regimen and bimonthly fixed-dosing regimen of aflibercept. One observational study of 42 eyes found a similar change in BCVA from baseline and complete polyp closure rate between a PRN regimen and bimonthly fixed-dosing regimen of aflibercept. One RCT of 249 eyes found a similar change in BCVA and RT from baseline, as well as polyp closure, between a T&E regimen and fixed 12-week dosing regimen of conbercept. One observational study of 30 eyes found a superiority of T&E aflibercept for change in BCVA and risk of polyp recurrence, compared to a PRN regimen.

conclusionOverall, there is a paucity of evidence comparing various treatment regimens of anti-VEGF therapy in patients with PCV. This limited evidence suggests that current treatment regimens are similarly efficacious, though T&E aflibercept achieved superior outcomes when compared to bimonthly dosing or PRN in some individual studies. Further trials are needed to confirm or refute these findings.

Indexed as

Angiogenesis InhibitorsPolypoidal Choroidal VasculopathyHumansIntravitreal InjectionsObservational Studies as TopicReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsAnti-VEGFAs-neededPolypoidal choroidal vasculopathyTreat-and-extend

Identifiers

PMID37591212
PMCPMC10659003
OpenAlexW4385968901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.